ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011

Trapido To Lead NCI’s Epidemiology Program.

July 26, 2002

In Congress: Clinton Backs Genetic Privacy Bills, But Plans Changes Proposals

July 18, 1997

NSABP Breast Cancer Prevention Trial Reports Final Results On Tamoxifen

November 25, 2005

AACR President: Cancer Program ‘Threatened,’ Calls For Strategic Plan, More Extramural Input

December 6, 1991

Obit: John Ultmann, A Leader In Clinical Oncology.

October 27, 2000